Compare ICCM & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ICCM | RFL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 54.4M |
| IPO Year | N/A | N/A |
| Metric | ICCM | RFL |
|---|---|---|
| Price | $0.66 | $1.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 375.3K | 143.0K |
| Earning Date | 11-19-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,975,000.00 | $1,029,000.00 |
| Revenue This Year | $13.67 | N/A |
| Revenue Next Year | $38.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.63 |
| 52 Week Low | $0.59 | $1.17 |
| 52 Week High | $1.66 | $3.19 |
| Indicator | ICCM | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 64.11 |
| Support Level | $0.67 | $1.21 |
| Resistance Level | $0.72 | $1.60 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 5.66 | 67.44 |
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.